Sera Prognostics, Inc. cash flow statement
In fiscal 2025, Sera Prognostics, Inc.'s operations generated −$25.6m of cash; it spent $726,000 on capital projects, leaving free cash flow of −$26.3m.
Cash flow statement
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | −17 | −32 | −35 | −27 | −14 | −26 | −28 |
| Depreciation and amortisation | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Stock-based pay | 1 | 3 | 5 | 5 | 7 | 5 | 4 |
| Capital spending | 0 | 1 | 1 | 0 | 0 | 1 | 0 |
| Free cash flow | −17 | −33 | −35 | −27 | −14 | −26 | −28 |
| Free cash flow after stock pay | −18 | −36 | −40 | −33 | −21 | −31 | −32 |
| Shares issued | — | — | — | — | — | 54 | 0 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −7 | −6 | −8 | −5 | −6 | −6 | −9 | −6 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −7 | −6 | −8 | −6 | −7 | −6 | −9 | −6 |
| Free cash flow after stock pay | −9 | −8 | −9 | −7 | −8 | −7 | −10 | −7 |
| Shares issued | 0 | — | 54 | 0 | 0 | 0 | 0 | 0 |
Compare with peers
- Aclarion, Inc. cash flow
- Ispecimen Inc. cash flow
- YD Bio Ltd cash flow
- Quantum-si Inc cash flow
- Bionexus Gene Lab Corp cash flow
Head to head: ACON vs SERAISPC vs SERASERA vs YDES
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies